Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
CoFactor phase IIb trial surpasses 50% enrollment milestone
March 9th, 2006
Adventrx Pharmaceuticals, Inc., (ANX) announced a CoFactor clinical development update at the BIO CEO conference in New York. The company announced patient recruitment has surpassed the half-way point in the CoFactor multi-national phase IIb clinical trial for metastatic colorectal cancer which was initiated in May 2005. The company also announced an update regarding its planned phase III clinical studies for CoFactor. The first phase III study will evaluate CoFactor in the first-line treatment of metastatic colorectal cancer. The second proposed phase III study would evaluate CoFactor in a third-line setting for advanced breast cancer. CoFactor...
Source: Women's Health Weekly (2006-03-09)
|
